ISIS Pharmaceuticals (ISIS) PT Raised to $91 at Needham & Company Amid Recent SMA Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
ISIS (ISIS) SMNRx Data Suggests Trends Going in Right Direction - Deutsche Bank
June 22, 2015 9:27 AM EDTDeutsche Bank reiterated a Buy rating on ISIS Pharmaceuticals (NASDAQ: ISIS) with a price target of $78. Earlier ISIS provided an update on children with SMA who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are continuing to receive treatment in an open-label extension (OLE) study. Analyst Alethia Young called the update incremental but sees trends heading in the right direction.
"We view this update on the children as... More
Isis Pharma (ISIS) Update on ISIS-SMNRx Phase 2 in SMA
June 22, 2015 7:04 AM EDTIsis Pharma (NASDAQ: ISIS) provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx and are continuing to receive treatment in an open-label extension (OLE) study. Consistent with earlier observations, increases in muscle function scores and additional motor function tests were observed in children treated with ISIS-SMNRx. Isis is currently collaborating with Biogen to develop and commercialize ISIS-SMNRx to treat patients with SMA.
"The natural course for children with untreated type II or type III SMA typically experience loss of muscle function... More
